[Mitomicyn C eye drops as alternative treatment for pyogenic granuloma in anophthalmic socket].
OBJECTIVE
To evaluate the efficacy of mitomycin C eye drops 0.02% concentration (0.02% MMC) in pyogenic granuloma in anophthalmic socket.


METHODS
Six patients who presented pyogenic granuloma were treated with 0.02% MMC four times a day in fifteen-day cycles with intervals of fifteen days between each cycle. The patients were observed every week.


RESULTS
Among the six studied patients, one presented a complete resolution of the pyogenic granuloma after a ten-day treatment with 0.02% MMC that is, before the end of the first cycle. In two patients, the treatment was successful after two weeks using 0.02% MMC (one complete cycle). In other two patients, the resolution of the lesion occurred after five weeks that is, at the beginning of the second cycle. 0.02% MMC was not successful in only one patient whose lesion persisted after two cycles of the treatment. None of the patients presented complications after the use of 0.02% MMC.


CONCLUSIONS
The topical use of 0.02% MMC proved efficacy in the treatment of anophthalmic socket pyogenic granuloma. A small number of patients took part in this study, therefore another randomized and comparative research is necessary in order to compare the efficacy of 0.02% MMC with other drugs such as corticosteroids and antimetabolites.
Santos
Hérika Danielle de Miranda
HD
Serviço de Plástica Ocular, Hospital São Geraldo, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.
Fernandes
Thatiana Almeida Pereira
TA
Diniz
Cristiano Menezes
CM
Montenegro
Wellington Tadeu
WT
Figueiredo
Ana Rosa Pimentel
AR
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000853:Anophthalmos / Q000150:complications*; D005260:Female; D005500:Follow-Up Studies; D017789:Granuloma, Pyogenic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D017678:Sex Distribution
D019384:Nucleic Acid Synthesis Inhibitors; D009883:Ophthalmic Solutions; D016685:Mitomycin